Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC

ABSTRACT:

SUBMITTER:  

PROVIDER: S-EPMC12332859 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature